Brian Wallach | |
---|---|
Born | October 9, 1980 |
Alma mater | Georgetown University (JD) Yale University |
Organization(s) | I AM ALS, Synapticure |
Spouse | Sandra Abrevaya (m. 2013) |
Children | 2 |
Website | https://iamals.org/ |
Brian Wallach (born October 9, 1980) is an American businessman, lawyer, and amyotrophic lateral sclerosis (ALS) research and patient advocate. He became known for his activism after being diagnosed with ALS in 2017. [1] Since then, Wallach has founded a nonprofit, I AM ALS, and a telemedicine company, Synapticure.
Wallach grew up in Washington, D.C., and attended Saint Albans School. He graduated from Yale University, where he participated in track and field. [2] Wallach later received his J.D. from Georgetown University Law Center. [3]
After law school, Wallach worked on the first presidential campaign for Barack Obama, where he met his wife, Sandra Abrevaya. He joined the presidential campaign in 2007 as its deputy political director for the New Hampshire primary. [3] After the campaign, he worked at a law firm before joining the White House counsel's office in 2011. [2] From there, Wallach became a federal criminal prosecutor in the U.S. Attorney's Office in Chicago. [4]
Wallach and his wife, Sandra Abrevaya, have co-founded two organizations focused on ALS. [5] In 2019, they launched I AM ALS, a non-profit seeking to find a cure for ALS through funding and expanding access to research. [2] In 2022 they founded Synapticure, a telemedicine company that provides care to those living with ALS, PLS, and Parkinson's. [4]
Wallach was diagnosed with ALS in 2017 at the age of 36 on the same day he and his wife brought home their second daughter from the hospital. [3] Originally visiting the doctor for a persistent cough, Wallach had also mentioned experiencing muscle tremors and weakness in his left hand and was told he probably had a progressive neurodegenerative disease. [2] After his diagnosis, Wallach was given six months to live. [6]
In January 2019, Wallach and Abrevaya launched I AM ALS. [7] In April of the same year, Wallach testified before Congress, advocating for ALS patients and research funding while sharing "what it's like to live with a fatal diagnosis." [8] Wallach argued that Congressional committees rarely heard from people diagnosed with ALS "because ALS is a relentless churn. We diagnose. We die, quickly. We don't have time to advocate." [3]
Wallach's testimony spurred a legislative process that eventually led to President Joe Biden's December 2021 signing into law of the Accelerating Access to Critical Therapies for ALS Act, while acknowledging the contribution, and detailing the story, of Wallach and Abrevaya. [9] This bill, which Wallach co-authored with others, provides expanded access to medications being studied in clinical trials to those who have been previously unable to participate. Also, this bill authorizes $100 million a year for five years to increase ALS research. [10]
The ALS Disability Insurance Access Act was initially introduced in 2017 to shorten the five-month wait time for ALS patients to access disability benefits. [11] A network of non-profits, including I AM ALS, advocated to move the bill forward, which the United States Senate passed in December 2020. [12]
In June 2022, Wallach threw out the first pitch before a Chicago Cubs game at Wrigley Field as part of Lou Gehrig Day to raise awareness for ALS. [13]
Wallach and Abrevaya were amongst those who testified at Congressional hearings advocating to have the Food and Drug Administration (FDA) approve the ALS drug sodium phenylbutyrate/ursodoxicoltaurine. [14] A network of non-profits, including I AM ALS, submitted more than 50,000 signatures to the FDA calling for approval of the drug. [14] In September 2022, the FDA approved it, making it the first new ALS drug in five years. [15]
In December 2022, Dan Tate, an I AM ALS Board Member, delivered an I AM ALS petition calling for the FDA to hold an Advisory Committee meeting on the drug NurOwn. [16] A July 2023 story by NPR described the work of Wallach and Abrevaya as having "changed the face of medical advocacy." [17]
Wallach and Abrevaya spoke on the first day of the 2024 Democratic National Convention. [18] [19]
In 2019, Wallach and Abrevaya started working with filmmaker Chris Burke, Wallach's friend from Yale to create the documentary, No Ordinary Campaign. [20] The film follows Wallach and Abrevaya as they travel across the US gathering information on the healthcare system's handling of rare and fatal diseases, and their work that led to increased federal funding, expanded access to therapies, and increased awareness of neurodegenerative diseases.
The documentary premiered in October 2022, at the Chicago International Film Festival, which featured a panel discussion with the film's executive producer, Katie Couric. [21] The film received the festival's Audience Choice Award: Best Documentary. [22]
For Love & Life: No Ordinary Campaign (updated title) became available for streaming on Prime Video on May 28, 2024.
The United States Food and Drug Administration is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, caffeine products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods & feed and veterinary products.
A medication is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management.
Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. Often, no symptoms are noticed initially. As it progresses, bone pain, anemia, renal insufficiency, and infections may occur. Complications may include hypercalcemia and amyloidosis.
Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder in which a proliferation of mature granulocytes and their precursors is found; characteristic increase in basophils is clinically relevant. It is a type of myeloproliferative neoplasm associated with a characteristic chromosomal translocation called the Philadelphia chromosome.
Fabry disease, also known as Anderson–Fabry disease, is a rare genetic disease that can affect many parts of the body, including the kidneys, heart, brain, and skin. Fabry disease is one of a group of conditions known as lysosomal storage diseases. The genetic mutation that causes Fabry disease interferes with the function of an enzyme that processes biomolecules known as sphingolipids, leading to these substances building up in the walls of blood vessels and other organs. It is inherited in an X-linked manner.
Muscular Dystrophy Association (MDA) is an American nonprofit organization dedicated to supporting people living with muscular dystrophy, ALS, and related neuromuscular diseases. Founded in 1950 by Paul Cohen, who lived with muscular dystrophy, MDA accelerates research, advances care, and works to empower families to live longer and more independent lives. Renowned for The MDA Labor Day Telethon, the annual telecast aired live every Labor Day weekend, with comedian and filmmaker Jerry Lewis as its host and national chairman. Don Rickles, Frank Sinatra, Sammy Davis Jr., Milton Berle, Wayne Newton, Norm Crosby, Don Francisco, Tony Orlando, Johnny Carson, Aretha Franklin, Maureen McGovern, Diana Ross, Angela Lansbury and others have supported MDA over the years. The organization's headquarters is in Chicago, Illinois.
Duchenne muscular dystrophy (DMD) is a severe type of muscular dystrophy predominantly affecting boys. The onset of muscle weakness typically begins around age four, with rapid progression. Initially, muscle loss occurs in the thighs and pelvis, extending to the arms, which can lead to difficulties in standing up. By the age of 12, most individuals with Duchenne muscular dystrophy are unable to walk. Affected muscles may appear larger due to an increase in fat content, and scoliosis is common. Some individuals may experience intellectual disability, and females carrying a single copy of the mutated gene may show mild symptoms.
Telehealth is the distribution of health-related services and information via electronic information and telecommunication technologies. It allows long-distance patient and clinician contact, care, advice, reminders, education, intervention, monitoring, and remote admissions. Telemedicine is sometimes used as a synonym, or is used in a more limited sense to describe remote clinical services, such as diagnosis and monitoring. When rural settings, lack of transport, a lack of mobility, conditions due to outbreaks, epidemics or pandemics, decreased funding, or a lack of staff restrict access to care, telehealth may bridge the gap as well as provide distance-learning; meetings, supervision, and presentations between practitioners; online information and health data management and healthcare system integration. Telehealth could include two clinicians discussing a case over video conference; a robotic surgery occurring through remote access; physical therapy done via digital monitoring instruments, live feed and application combinations; tests being forwarded between facilities for interpretation by a higher specialist; home monitoring through continuous sending of patient health data; client to practitioner online conference; or even videophone interpretation during a consult.
Expanded access or compassionate use is the use of an unapproved drug or medical device under special forms of investigational new drug applications (IND) or IDE application for devices, outside of a clinical trial, by people with serious or life-threatening conditions who do not meet the enrollment criteria for the clinical trial in progress.
Fast track is a designation by the United States Food and Drug Administration (FDA) of an investigational drug for expedited review to facilitate development of drugs that treat a serious or life-threatening condition and fill an unmet medical need. Fast track designation must be requested by the drug company. The request can be initiated at any time during the drug development process. FDA will review the request and attempt to make a decision within sixty days.
Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma, comprising about 6% of cases. It is named for the mantle zone of the lymph nodes where it develops. The term 'mantle cell lymphoma' was first adopted by Raffeld and Jaffe in 1991.
The "war on cancer" is the effort to find a cure for cancer by increased research to improve the understanding of cancer biology and the development of more effective cancer treatments, such as targeted drug therapies. The aim of such efforts is to eradicate cancer as a major cause of death. The signing of the National Cancer Act of 1971 by United States president Richard Nixon is generally viewed as the beginning of this effort, though it was not described as a "war" in the legislation itself.
Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig's disease in the United States, is a rare, terminal neurodegenerative disorder that results in the progressive loss of both upper and lower motor neurons that normally control voluntary muscle contraction. ALS is the most common form of the motor neuron diseases. ALS often presents in its early stages with gradual muscle stiffness, twitches, weakness, and wasting. Motor neuron loss typically continues until the abilities to eat, speak, move, and, lastly, breathe are all lost. While only 15% of people with ALS also fully develop frontotemporal dementia, an estimated 50% face at least some minor difficulties with thinking and behavior. Depending on which of the aforementioned symptoms develops first, ALS is classified as limb-onset or bulbar-onset.
An Emergency Use Authorization (EUA) in the United States is an authorization granted to the Food and Drug Administration (FDA) under sections of the Federal Food, Drug, and Cosmetic Act as added to and amended by various Acts of Congress, including by the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), as codified by 21 U.S.C. § 360bbb-3, to allow the use of a drug prior to approval. It does not constitute approval of the drug in the full statutory meaning of the term, but instead authorizes the FDA to facilitate availability of an unapproved product, or an unapproved use of an approved product, during a declared state of emergency from one of several agencies or of a "material threat" by the Secretary of Homeland Security.
Right-to-try laws are United States state laws and a federal law that were created with the intent of allowing terminally ill patients access to experimental therapies that have completed Phase I testing but have not been approved by the Food and Drug Administration (FDA). Prior to the passage of right to try laws, patients needed FDA approval to use experimental drugs. As of 2018, 41 U.S. states had passed right to try laws. The framers of these laws argue that this allows for individualized treatments that are not permitted under the FDA's current regulatory scheme. The value of these laws was questioned on multiple grounds, including the fact that pharmaceutical manufacturers would have no obligation to provide the therapies being sought. A federal right to try law was passed in May 2018. Very little data is available about the number of patients who have used the right-to-try pathway, but available sources indicate that since the signing of the bill only a handful of patients have used this pathway to access experimental therapies, as most physicians and sponsors prefer the more traditional, FDA approved, Expanded Access route. According to Scott Gottlieb, who served as commissioner of the FDA under President Donald Trump, the FDA had already approved 99% of patient requests for access to experimental drugs, either immediately over the phone or within a few days, prior to the passage of right to try legislation.
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.
The 21st Century Cures Act is a United States law enacted by the 114th United States Congress in December 2016 and then signed into law on December 13, 2016. It authorized $6.3 billion in funding, mostly for the National Institutes of Health. The act was supported especially by large pharmaceutical manufacturers and was opposed especially by some consumer organizations.
Artificial intelligence in healthcare is the application of artificial intelligence (AI) to copy human cognition in the analysis, presentation, and understanding of complex medical and health care data. It can also augment and exceed human capabilities by providing faster or new ways to diagnose, treat, or prevent disease. Using AI in healthcare has the potential improve predicting, diagnosing and treating diseases. Through machine learning algorithms and deep learning, AI can analyse large sets of clinical data and electronic health records and can help to diagnose the disease more quickly and precisely.
Aid Access is a nonprofit organization that provides access to medication abortion by mail to the United States and worldwide. It describes its work as a harm reduction strategy designed to provide safe access to mifepristone and misoprostol for those able to become pregnant in the United States who may not otherwise have access to abortion or miscarriage management services. People are able to manage their own abortion with remote access to a physician and a help-desk for any questions. The website is available in English, Spanish, and Dutch.
The n-Lorem Foundation is a non-profit organization based in Carlsbad, California, established to develop personalized medicines using antisense RNA in order to treat patients of rare diseases.